Lipoatrophy in patients with AIDS: Treatment with polymethylmethacrylate in Amazonas, Brazil

International Journal of Dermatology

Volumn 50, Issue 10, 2011, Pages 1255-1258

  Orsi, Ana Tereza ^a   Miranda, Angélica Espinosa ^a,b   Souza, Andrea Cavalcante ^a   Silva, Leila Cristina ^a   Dias, Gisele Reis ^a   Talhari, Carolina ^a,c   Talhari, Sinesio ^a   Santos, Monica ^a,c  

^a Fundac ao de Medicina Tropical do Amazonas   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c Universidade Estadual do Amazonas   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

POLY(METHYL METHACRYLATE); STAVUDINE; ZIDOVUDINE;

ACADEMIC ACHIEVEMENT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAZIL; CLINICAL ARTICLE; EDEMA; FEMALE; FOLLOW UP; GRANULOMA; HUMAN; INTERVIEW; LIPOATROPHY; MALE; PAIN; PATIENT SATISFACTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; FACIAL DERMATOSES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; POLYMETHYL METHACRYLATE;

EID: 80053194535     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04926.x     Document Type: Article

References (16)

1. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-131.
2. Alves C, Oliveira AC, Brites C. Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. Braz J Infect Dis 2008; 12: 342-348.
3. Boyd M, Reiss P. The long-term consequences of antiretroviral therapy: a review. J HIV Ther 2006; 11: 26-35.
4. Bechara FG, Sand M, Potthoff A, et al. HIV-associated facial lipoatrophy - review of current therapy options. Eur J Med Res 2008; 13: 93-99.
5. Shibuyama S, Gevorkyan A, Yoo U, et al. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006; 12: 1075-1090.
6. Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; 9: 849-863.
7. Panse I, Vasseur E, Raffin-Sanson ML, et al. Lipodystrophy associated with protease inhibitors. Br J Dermatol 2000; 142: 496-500.
8. Ministério da Saúde. Manual de Tratamento Lipoatrofia facial em pacientes portadores de HIV/AIDS com polimetilmetacrilato (PMMA). Brasília: Programa Nacional de DST/AIDS; 2005: 17-26.
9. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg 2006; 32: 1336-1345.
10. Jones DH, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004; 30: 1279-1286.
11. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-1818.
12. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139-147.
13. Hansen AB, Lindegaard B, Obel N, et al. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6years compared with the background population. HIV Med 2006; 7: 38-45.
14. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41: 590-597.
15. Carruthers A, Carruthers J. Polymethylmethacrylate microspheres/collagen as a tissue augmentation agent: personal experience over 5years. Dermatol Surg 2005; 31: 1561-1565.
16. Carvalho Costa IM, Salaro CP, Costa MC. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9years. Dermatol Surg 2009; 35: 1221-1227.